CYP2C9*3 and*13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects

European Journal of Clinical Pharmacology

Volumn 68, Issue 2, 2012, Pages 149-154

  Choi, Chang Ik ^a   Kim, Mi Jeong ^a   Chung, Eun Kyung ^a   Lee, Hye In ^a   Jang, Choon Gon ^a   Bae, Jung Woo ^a,b   Lee, Seok Yong ^a  

^a Sungkyunkwan University   (South Korea)

^b Keimyung University   (South Korea)

Author keywords

CYP2C9; Genetic polymorphism; Irbesartan; Pharmacokinetics

Indexed keywords

APROBEL; IRBESARTAN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; CYP2C9 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; GENE; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; KOREAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALLELES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BIPHENYL COMPOUNDS; GENOTYPE; HALF-LIFE; HUMANS; POLYMORPHISM, GENETIC; TETRAZOLES;

EID: 84857051046     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1098-0     Document Type: Article

References (27)

1. MR Marino NN Vachharajani 2001 Drug interactions with irbesartan Clin Pharmacokinet 40 605 614 11523726 10.2165/00003088-200140080-00004 1:CAS:528:DC%2BD3MXmsl2gsb8%3D (Pubitemid 32758582)
2. L Perrier M Bourrié E Marti C Tronquet D Massé Y Berger J Magdalou G Fabre 1994 In vitro N-glucuronidation of SB 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions J Pharmacol Exp Ther 271 91 99 7965761 1:CAS:528:DyaK2MXhvVyqtr8%3D (Pubitemid 24333117)
3. M Bourrié V Meunier Y Berger G Fabre 1999 Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes Drug Metab Dispos 27 288 296 9929518 (Pubitemid 29072087)
4. JC Gillis A Markham 1997 Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension Drugs 54 885 902 9421695 10.2165/00003495-199754060-00007 1:CAS:528: DyaK1cXht1Ojug%3D%3D (Pubitemid 27526898)
5. MR Marino K Langenbacher NF Ford HD Uderman 1998 Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects J Clin Pharmacol 38 246 255 9549663 1:CAS:528:DyaK1cXisFSlsbc%3D (Pubitemid 28144930)
6. D Van Booven S Marsh H McLeod MW Carrillo K Sangkuhl TE Klein RB Altman 2010 Cytochrome P450 2C9-CYP2C9 Pharmacogenet Genomics 20 277 281 20150829
7. JO Miners DJ Birkett 1998 Cytochrome P4502C9: an enzyme of major importance in human drug metabolism Br J Clin Pharmacol 45 525 538 9663807 10.1046/j.1365-2125.1998.00721.x 1:CAS:528:DyaK1cXktFaitro%3D (Pubitemid 28270907)
8. CR Lee JA Goldstein JA Pieper 2002 Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data Pharmacogenetics 12 251 263 11927841 10.1097/00008571-200204000-00010 1:CAS:528:DC%2BD38XnsFKqsLc%3D Erratum in: (2002) Pharmacogenetics 12:343 (Pubitemid 34596790)
9. Y Guo Y Zhang Y Wang X Chen D Si D Zhong JP Fawcett H Zhou 2005 Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans Drug Metab Dispos 33 749 753 15764711 10.1124/dmd.105.003616 1:CAS:528:DC%2BD2MXksleksr0%3D (Pubitemid 40686627)
10. Z Li G Wang LS Wang W Zhang ZR Tan L Fan BL Chen Q Li J Liu JH Tu DL Hu ZQ Liu HH Zhou 2009 Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects Xenobiotica 39 788 793 19604036 10.1080/00498250903134435 1:CAS:528:DC%2BD1MXhtVOms77E
11. JW Bae CI Choi CG Jang SY Lee 2011 Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam Br J Clin Pharmacol 71 550 555 21395648 10.1111/j.1365-2125.2010.03853.x 1:CAS:528:DC%2BC3MXltVKrtb8%3D
12. E García-Martín C Martínez JM Ladero JA Agúndez 2006 Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals Mol Diagn Ther 10 29 40 16646575
13. K Nakai W Habano K Nakai N Fukushima A Suwabe S Moriya K Osano D Gurwitz 2005 Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations Life Sci 78 107 111 16111713 10.1016/j.lfs.2005.04.049 1:CAS:528:DC%2BD2MXhtFKmsLzO (Pubitemid 41527238)
14. JW Bae HK Kim JH Kim SI Yang MJ Kim CG Jang SY Lee 2005 Allele and genotype frequencies of CYP2C9 in a Korean population Br J Clin Pharmacol 60 418 422 16187974 10.1111/j.1365-2125.2005.02448.x 1:CAS:528:DC%2BD2MXhtFylt73E (Pubitemid 41428473)
15. D Si Y Guo Y Zhang L Yang H Zhou D Zhong 2004 Identification of a novel variant CYP2C9 allele in Chinese Pharmacogenetics 14 465 469 15226678 10.1097/01.fpc.0000114749.08559.e4 1:CAS:528:DC%2BD2cXlt1Ckt74%3D (Pubitemid 38971236)
16. K Maekawa N Harakawa E Sugiyama M Tohkin SR Kim N Kaniwa N Katori R Hasegawa K Yasuda K Kamide T Miyata Y Saito J Sawada 2009 Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects Drug Metab Dispos 37 1895 1903 19541829 10.1124/dmd.109.027003 1:CAS:528: DC%2BD1MXhtVOrsrbP
17. SA Scott R Khasawneh I Peter R Kornreich RJ Desnick 2010 Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups Pharmacogenomics 11 781 791 20504253 10.2217/pgs.10.49 1:CAS:528:DC%2BC3cXmsFSnt7g%3D
18. WD Dupont WD Plummer 1998 Power and sample size calculations for studies involving linear regression Control Clin Trials 19 589 601 9875838 10.1016/S0197-2456(98)00037-3 1:STN:280:DyaK1M%2FptFSnsA%3D%3D (Pubitemid 29057724)
19. J Kirchheiner S Bauer I Meineke W Rohde V Prang C Meisel I Roots J Brockmöller 2002 Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers Pharmacogenetics 12 101 109 11875364 10.1097/00008571-200203000-00004 1:CAS:528:DC%2BD38XnsFKqsb0%3D (Pubitemid 34298914)
20. MG Scordo V Pengo E Spina ML Dahl M Gusella R Padrini 2002 Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance Clin Pharmacol Ther 72 702 710 12496751 10.1067/mcp.2002. 129321 1:CAS:528:DC%2BD3sXlt1Sjug%3D%3D (Pubitemid 36021009)
21. CR Lee JA Pieper RF Frye AL Hinderliter JA Blaisdell JA Goldstein 2003 Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans J Clin Pharmacol 43 84 91 12520632 10.1177/0091270002239710 1:CAS:528: DC%2BD3sXkvVGlsA%3D%3D (Pubitemid 36015447)
22. YH Zhou QC Zheng ZS Li Y Zhang M Sun CC Sun D Si L Cai Y Guo H Zhou 2006 On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study Biochimie 88 1457 1465 16740353 10.1016/j.biochi.2006.05.001 1:CAS:528:DC%2BD28XhtFOhsrvL (Pubitemid 44667213)
23. Y Guo Y Wang D Si PJ Fawcett D Zhong H Zhou 2005 Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13 Xenobiotica 35 853 861 16308280 10.1080/00498250500256367 1:CAS:528:DC%2BD2MXht1Gltb%2FI (Pubitemid 41759171)
24. X Hong S Zhang G Mao S Jiang Y Zhang Y Yu G Tang H Xing X Xu 2005 CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population Eur J Clin Pharmacol 61 627 634 16094537 10.1007/s00228-005- 0976-8 1:CAS:528:DC%2BD2MXhtFahtb3F
25. G Chen S Jiang G Mao S Zhang X Hong G Tang Z Li X Liu Y Zhang H Xing B Wang Y Yu X Xu 2006 CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients Methods Find Exp Clin Pharmacol 28 19 24 16541193 10.1358/mf.2006.28.1.962773
26. P Hallberg J Karlsson L Kurland L Lind T Kahan K Malmqvist KP Ohman F Nyström H Melhus 2002 The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial J Hypertens 20 2089 2093 12359989 10.1097/00004872-200210000-00030 1:CAS:528:DC%2BD38XnsVeqtLY%3D (Pubitemid 35305508)
27. SY Wen H Wang OJ Sun SQ Wang 2003 Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray World J Gastroenterol 9 1342 1346 12800253 1:CAS:528:DC%2BD3sXlvVSqsbw%3D (Pubitemid 36805681)